Strategically, the company aims to combine technology with pharmaceuticals or human bio molecules in order to offer to the marketplace a unique and patented dosage form. The starting point to the business is a bank of available, patented and toxicologically acceptable technology. The uniqueness may be demonstrated in some of the following ways: the reduction of adverse effects, more precise targeting of the active constituent, the elimination of undesirable blood level concentrations, enhanced compliance and an accessibility to other indications.

The company operates in two ways and in both cases we draw on our technology in order to develop a unique dosage form. According to the first approach, CT identifies the market opportunity and funds the pre-clinical and early clinical investigations. However, the company will also seek partners with a commercial interest in specific product developments. These partners will generally finance the development effort, with CT retaining the rights to manufacture and supply the product for clinical trials and to the market.

If the development of a product has been funded by CT according to the first approach, the company would seek to establish marketing agreements as soon as clinical results provide clear evidence of future commercial success. As an example, our dinoprostone controlled release vaginal pessary was licensed to Forest Laboratories of New York for marketing as Cervidil® in the USA. Ferring NV was appointed as market partner for the EU and South Africa, using the trademark Propess® whilst they use the Cervidil® trademark in Canada. Manufacture of the product takes place at East Kilbride and the sales revenue is shared according to an agreed formula.

Alternatively, where a partner company funds the product development from the outset through milestone payments, based on the partner’s own or selected active component, the partner maintains the marketing rights for all or selected territories according to the terms of the agreement.